Albireo
Arvid Wallgrens Backe 20
413 46 Gothenburg
Gothenburg
413 46
Tel: 46-31-7411480
Fax: 46-31-820223
Website: http://www.albireopharma.com/
99 articles about Albireo
-
Albireo Reports Q2 Financial Results and Business Update
8/5/2021
Albireo Pharma, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2021.
-
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
8/3/2021
Albireo Pharma, Inc. today announced that Ron Cooper, President and Chief Executive Officer and Simon Harford, Chief Financial Officer, will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 10, at 3:30 p.m. ET.
-
It will immediately begin to sell Bylvay to treat patients impacted by PFIC, a rare cholestatic liver disease that often leads to cirrhosis and liver failure within the first ten years of life.
-
There are two PDUFA dates on the U.S. Food and Drug Administration’s calendar for this week. Here’s a look.
-
Albireo to Present at the William Blair Biotech Focus Conference 2021
7/8/2021
Albireo Pharma, Inc. today announced that Ron Cooper, President and Chief Executive Officer, will present at the William Blair Biotech Focus Conference on Thursday, July 15, at 11:00 a.m. EDT.
-
Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
6/24/2021
Albireo Pharma, Inc. today announced that Ron Cooper, President and Chief Executive Officer, will present as part of a fireside chat at Piper Sandler’s Virtual EASL Takeaway Day on Monday, June 28, at 10:00 a.m. EDT.
-
Albireo Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming EASL International Liver Congress
6/21/2021
Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced new data in nine accepted abstracts to be presented at EASL International Liver Congress™ 2021 on June 23 – 26.
-
Albireo to Showcase New Data at the EASL International Liver Congress™ 2021
6/10/2021
Albireo Pharma, Inc.today announced the presentation of data at the European Association for the Study of the Liver (EASL).
-
Albireo to Present at Upcoming Jefferies and William Blair Virtual Investor Conferences
5/26/2021
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present as part of fireside chats at both the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, at 9:30 a.m. EDT and William Blair’s 41 st Annual Growth Stock Conference on Thursday, June 3, at 12:40 p.m. EDT.
-
Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
5/21/2021
– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus (P=0.004) primary endpoints, with a diarrhea rate of 10% vs 5% placebo – – Integrated EU commercial, access and medical organization in place ready to launch following EU marketing authorization –
-
Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5/19/2021
- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC - - Data showing long-term treatment benefits of Bylvay™ (odevixibat ) , including improvements in total bilirubin, growth, and sleep –
-
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021
5/7/2021
Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.
-
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
4/13/2021
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs – – Deep experience spanning drug development, manufacturing, quality and supply chain
-
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
4/6/2021
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the upcoming Needham 20th Annual Healthcare Conference on April 12-15.
-
Albireo Announces First Patients Dosed in Two New Studies
3/25/2021
– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome –
-
Albireo to Host Virtual Investor Commercial Day 2021
1/7/2021
- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST. Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for o
-
Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
1/5/2021
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in the H.C. Wainwright Virtual BioConnect 2021 Conference to be held January 11-14, 2021 and the LifeSci Advisors 10th Annual Corporate Access Event to be held January 6-14, 2021. The virtual LifeSci Advisors event presentation will be live at 1
-
Albireo Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/11/2020
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock options are exercisable at a price of $39.77 per share, the closing price of Albireo’s common stock on December 9, 2020, the grant date, and were granted as inducements material to the em
-
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
11/13/2020
- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term extension study show sustained improvements in serum bile acids, pruritus - - Improvements in growth measures and liver parameters observed with long-term administration suggests disease modifying potential of odevixibat - -
-
Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
11/12/2020
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Healthcare Conference on November 19 at 12 p.m. EST. The Company will also be participating in the virtual Piper Sandler 32nd Annual Healthcare Conference being held December 1-3. A live audio webcast of the